Apheresis Equipment Market Size, Share & Trends Analysis Report By Application (Renal Diseases, Haematology, Neurology), By Procedure (Plasmapheresis, LDL-Apheresis, Plateletpheresis, Leukapheresis), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global apheresis equipment market was valued at USD 2.66 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 10.94% from 2023 to 2030. The rising prevalence of blood-related disorders and the availability of favorable government initiatives along with reimbursement frameworks are expected to drive the market growth. Further, the rising popularity and participation in blood donation drives and camps along with the growing number of blood transfusions are anticipated to support the demand for apheresis equipment during the forecast period.

The rising prevalence of chronic diseases such as autoimmune diseases and cancer is anticipated to boost the market growth. According to National Stem Cell Foundation (NSCF), approximately 4% of the world's population suffers from one of over 80 different autoimmune diseases. Autoimmune diseases are the third leading cause of chronic disease in the U.S.For instance, according to Johns Hopkins Medicine Pathology, all autoimmune diseases together affect about 3% of the U.S. population, which is about 10 million people. Therapeutic plasma exchange (TPE) is widely used for the treatment of autoimmune diseases.

The rise in the number of platelet donors and R&D investments by biopharmaceutical companies are expected to bode well with the market. According to the Centers for Disease Control and Prevention, hemophilia A affects around one in every 5,000 male births. Around 400 babies are born with hemophilia every year.

The growing demand for the different components of the blood, and the raising complex surgical approaches are increasing the demand for apheresis equipment. As per The American National Red Cross, around 29,000 units of RBCs are needed daily in the U.S. Approximately 16 million blood components are transfused each year. However, the market's expansion is being hampered by risk with apheresis devices, as well as a lack of donor availability and histocompatibility.

COVID-19 apheresis equipment market impact: 8.0% increase from 2020 to 2021

The increasing government support and investment in apheresis equipment are driving the market growth. For instance, the Guyana Ministry of Public Health ordered a Trima Accelerated Automated Blood Collection System, which is worth USD 94,000 in 2021, in order to boost the service capacity of the National Blood Transfusion Service (NBTS) department. This modern apheresis machine will help the National Blood Transfusion Service expand its capacity.

Product Insights

Based on product, the apheresis equipment market is bifurcated into disposable apheresis kits and devices. The disposable apheresis kit segment dominated the market with a share of almost 73% in 2022 and is anticipated to maintain its dominance over the forecast period owing to the extensive advancement in the manufacturing of blood bags, disposable kits, and tubing. Growing demand for automated component separation procedures, especially in the developed markets is driving the segment growth.

The disposable kits are mostly used by patients with thrombocytopenia and severely reduced platelet function. Thus, the availability of high-quality kits for optimal patient treatment is expected to fuel the segment growth. Furthermore, the growing acceptability of disposable apheresis kits, owing to their low prices, has generated a variety of services for small manufacturers. Kits are bundled together and are inclusive of filters, separators, tubing sets, and other components. High usage volume and rapidly growing demand for apheresis procedures are some factors attributing to its large share. In addition, single usage helps in limiting device-related blood infections in donors and patients, thereby boosting segment growth.

The device segment is expected to have a significant growth rate during the forecast period. The growth can be attributed to various factors including improving healthcare infrastructure, growing demand for automated blood component separators, and increased blood donation activities. The introduction of sophisticated and automated apheresis machines and growing demand in emerging countries are expected to drive the segment growth.

Procedure Insights

Based on procedure, the plasmapheresis segment accounted for the largest revenue share of 53.3% in 2022. As plasma-based medications are delivered to patients with weakened immune systems in an attempt to boost infection and disease resistance. The segment is expected to develop as the incidence of blood-related diseases rises and the demand for plasma-derived therapies grows.

Plasmapheresis is the process of separating white blood cells (WBC) from the blood that is drained from the body. This type of surgery is essential for the treatment of T-cell lymphoma (CTCL) and graft-versus-host disease (GvHD) and this is expected to boost the demand for plasmapheresis. For instance, U. S. Department of Defence started collecting 8,000 donated units of plasma from patients who have recovered from COVID-19 in May 2020 in order to aid in the discovery of a viable treatment for the condition. Plasmapheresis equipment and disposables are now widely used in the U.S. for this initiative.

The leukapheresis segment is expected to witness lucrative growth during the forecast period. Increasing cancer incidence rates particularly breast & prostate cancer and leukemia are expected to boost usage rates during the forecast period. For instance, in January 2022, according to the American Cancer Society, there are an estimated 60,650 new cases of leukemia in the U.S. It was also estimated that there were 24,000 deaths recorded in 2022 due to leukemia in the U.S.

Application Insights

Based on application, the market is divided into renal diseases, hematology, neurology, and others. The neurology segment accounted for the largest share of revenue in 2022. The indispensable need for therapeutic apheresis in the treatment of highly prevalent neurological disorders such as multiple sclerosis and autoimmune neurological disorder are factors attributed to the dominant share of the segment.

As per the Atlas of MS, multiple sclerosis affected approximately 2.8 million persons worldwide (35.9% of the population). The average age of diagnosis is 32 years, and the aggregated incidence rate across 75 reporting nations is 2.1 per 100,000 people each year. Multiple sclerosis affects twice as many women as it does men. Furthermore, rising R&D and favorable government initiatives for neurological disorders are expected to speed up segmental growth.

The haematology segment is expected to have significant growth throughout the forecast period. The high growth of the segment can be attributed to the increasing prevalence of blood disorders. According to The American National Red Cross, around 90,000 to 100,000 people are suffering from sickle cell disease in the U.S. Additionally, about 1,000 babies are born with the disease every year. Patients suffering from sickle cell disease may require blood transfusions throughout their lives.

Technology Insights

Based on technology, the centrifugation device segment held the largest revenue share of 57% in 2022. Centrifugation offers faster, simpler, and more precise results as compared to membrane filtration and this attributes to its higher usage rates. Furthermore, growing demand for automated apheresis systems is expected to augment the segment growth. Companies are creating technologically advanced and automated devices to improve product efficiency. Automatic apheresis equipment with continuous flow centrifugation, an automated interface system, and a tailored anticoagulant infusion system are being developed by the manufacturers.

The use of automated technology has resulted in a more efficient and quick blood separation procedure. For instance, Haemonetics Corp has developed NexSys PCS, an automated system that boosts efficiency while also improving quality and compliance in plasma collection centers. Membrane filters are significantly useful in the infiltration of plasma from other cellular components as opposed to centrifuges, which are useful for specific cell separation. This method is less time-consuming and avoids depletion of blood coagulation factors and, thus, decreases the need for replacement fluids. The higher efficacy exhibited by this technology accounts for its high usage in the developed Western European regions and Japan.

Regional Insights

North America led the overall market with a revenue share of 35.2% in 2022 and is expected to continue this trend during the forecast period. The rising prevalence of blood-related diseases such as kidney disease, metabolic disease, cancer, and neurological disorders, the increasing number of donors, and the demand for blood components are the primary factors driving the market in North America. According to The American National Red Cross, nearly 6.8 million people donated blood in the U.S. every year. Furthermore, every 2 seconds, someone needs blood or platelets Thus, the rising number of blood transfusions and increasing number of donation camps are propelling the market in the U.S.

The Asia Pacific market, on the other hand, is expected to register the highest CAGR. The growing prevalence of blood disorders requiring plasma and platelet transfusion in emerging countries such as India and China is one of the key factors accounting for this growth in revenue share. In addition, improving healthcare infrastructure and increasing the number of healthcare practitioners in this region are expected to present the industry with a robust growth platform during the forecast period.

Key Companies & Market Share Insights

The market is oligopolistic in nature and is marked by an extensive presence of mergers and acquisitions. New product developments, acquisitions, and strategic alliances are some major sustainability strategies adopted by industry players. For instance, in October 2020, Haemonetics received US FDA 510(k) approval for its NexSys PCS system with Persona technology. In January 2020, Fresenius Kabi spent EUR 30 million in order to build an apheresis and transfusion disposables plant in the Dominican Republic. Some of the prominent players in the apheresis equipment market include:

• B. Braun Melsungen AG

• Haemonetics Corporation

• Fresenius KabiAG

• Asahi Kasei Medical Co., Ltd.

• Terumo BCT, Inc.

• Mallinckrodt

• Nikkiso Europe GmbH

Apheresis Equipment Market Report Scope

Global Apheresis Equipment Market Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global apheresis equipment market report based on product, procedure, application, technology, and region:

• Product Outlook (Revenue, USD Million, 2017 - 2030)

  • Disposable Apheresis Kits

  • Device

• Application Outlook (Revenue, USD Million, 2017 - 2030)

  • Renal Diseases

  • Haematology

  • Neurology

  • Others

• Procedure Outlook (Revenue, USD Million, 2017 - 2030)

  • Plasmapheresis

  • LDL apheresis

  • Plateletpheresis

  • Leukapheresis

  • Photopheresis

  • Erythrocytapheresis

  • Others

• Technology Outlook (Revenue, USD Million, 2017 - 2030)

  • Membrane Filtration

  • Centrifugation

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait